TELA Bio (NASDAQ:TELA – Get Free Report) is one of 510 public companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare TELA Bio to similar companies based on the strength of its dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
Analyst Recommendations
This is a summary of recent recommendations and price targets for TELA Bio and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TELA Bio | 1 | 1 | 4 | 0 | 2.50 |
| TELA Bio Competitors | 4324 | 10556 | 18357 | 840 | 2.46 |
TELA Bio presently has a consensus target price of $2.14, indicating a potential upside of 211.24%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 28.81%. Given TELA Bio’s stronger consensus rating and higher probable upside, analysts clearly believe TELA Bio is more favorable than its rivals.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| TELA Bio | -53.57% | -1,320.81% | -60.17% |
| TELA Bio Competitors | -191.34% | -187.68% | -21.85% |
Institutional and Insider Ownership
94.3% of TELA Bio shares are held by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 1.1% of TELA Bio shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares TELA Bio and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| TELA Bio | $80.28 million | -$38.83 million | -0.93 |
| TELA Bio Competitors | $1.87 billion | $136.77 million | 5.94 |
TELA Bio’s rivals have higher revenue and earnings than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
TELA Bio has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, TELA Bio’s rivals have a beta of 2.58, indicating that their average share price is 158% more volatile than the S&P 500.
Summary
TELA Bio rivals beat TELA Bio on 7 of the 12 factors compared.
TELA Bio Company Profile
TELA Bio is a medical technology company that develops and markets products for soft-tissue reconstruction. Its portfolio includes OviTex Reinforced Tissue Matrices, which combine biologic materials derived from ovine (sheep) tissue with polymer reinforcement. The products are designed to support tissue repair and are used in procedures including hernia and abdominal wall reconstruction. The company also offers products for plastic and reconstructive surgery, including OviTex PRS, and other solutions for soft-tissue repair.
Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.
